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Abstract 
A systematic review of early clinical outcomes in tuberculosis was undertaken to determine 
ranking of efficacy of drugs and combinations, define variability of these measures on different 
endpoints, and to establish the relationships between them. Studies were identified by searching 
PubMed, MEDLINE, EMBASE, LILACs and reference lists of included studies. Outcomes 
were early bactericidal activity results over two, seven and 14 days, and the proportion of 
patients with negative culture at eight weeks. 133 trials reporting Phase IIA (early bactericidal 
activity) and IIB (culture-conversion at two months) outcomes were identified. Only nine drug 
combinations were assessed on more than one Phase IIA endpoint and only three were assessed 
in both Phase IIA and IIB trials. The existing evidence base supporting Phase II methodology 
in tuberculosis is highly incomplete. In future, a broader range of drugs and combinations 
should be more consistently studied across a greater range of Phase II endpoints.  
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Introduction 
First-line tuberculosis therapy has remained unchanged for forty years. While “short-course” 
treatment is effective in clinical trials, in practice the six months required for successful cure 
is burdensome for patients and tuberculosis programmes. Identifying new and ultra-short 
regimens will require identification of suitable surrogate outcomes to facilitate progression of 
novel treatment regimens through Phase II to Phase III trials and de-risk drug development [1].  
The current “gold standard” Phase III endpoint is a composite of treatment failure and relapse 
up to 24 months following treatment completion. Use of this binary outcome which is rare in 
the comparator arm (<5% with standard short course regimens) mandates large sample sizes to 
adequately power clinical trials. The prolonged follow-up required further adds to trial costs, 
making the definitive outcome unsuitable for extensive evaluation of drug combinations or 
dose-finding. 
Numerous surrogate outcomes have been used for these purposes in Phase II. Phase IIA studies 
of “early bactericidal activity” (EBA) based on quantitative sputum bacteriology enrol small 
patient numbers for up to two weeks [2]. While the original rationale for such studies was dose-
finding for single agents, more recent studies have evaluated drug combinations [3, 4]. This 
concept has been extended into larger Phase IIB studies with combination therapy lasting up 
to two months [5]. The most studied Phase IIB outcome has been sputum culture conversion at 
fixed time-points, usually two months [6-8]. This endpoint is supported by regulators for 
conditional approval of novel drugs [9], but there remains a lack of consensus amongst trialists 
as to the utility of EBA studies and of other approaches to intermediate bacteriological data 
such as time-to-event and regression modelling [10].  
A complete understanding of the performance of TB treatment regimens in early phase clinical 
trials is critical to understanding their usefulness in predicting Phase III trial results and in 
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calibrating preclinical models of treatment. While the goals of historical Phase IIA and IIB 
regimens are distinct, with the former focussing on proof-of-concept for individual drugs and 
the latter on identifying the best combinations of drugs, it seems important to understand 
whether this information can be transmitted rationally through these phases. We undertook a 
systematic review of early clinical outcomes in tuberculosis (within the first two months of 
treatment), focusing on the key drugs comprising modern and historical first-line treatment 
regimens, to determine the overall ranking of efficacy of drugs and combinations, to define the 
variability of these measures of effect on the different endpoints used, and to establish the 
relationships between them.  
 
Methods 
The review included randomised clinical trials (RCTs) including patients with smear- and 
culture-positive pulmonary tuberculosis, being treated for the first time or with known isoniazid 
mono-resistant organisms, and including regimens containing any combination of historic or 
novel drugs used or proposed for use in first-line treatment regimens. Pre-defined outcomes of 
interest were EBA over two (EBA0-2), seven (EBA0-7) and 14 days (EBA0-14), and the 
proportion of patients with negative culture results at eight weeks. A systematic search of 
databases was conducted on 12th December 2016 (see Appendix). Risk of bias was 
considered.[11] Pooled estimates of each outcome for each drug or combination were obtained. 
Meta-regression was used to examine the impact of clinical covariates on the effect size of 
culture results at eight weeks. Analyses were performed using R version 2.14.1 [12]. Full 
methodology is detailed in the Appendix. 
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Results 
Included Studies 
Figure 1 shows the number of studies included at each stage of the review. The main reasons 
for exclusion were failure to meet the inclusion criteria, specifically previously-treated or drug-
resistant patients, and study design other than RCT. 133 relevant studies were identified which 
reported outcomes of interest. Of these, 37 were Phase II studies and 96 were Phase III studies 
reporting intermediate bacteriological outcomes. All 96 Phase III studies contributed to the 
Phase IIB outcome only – no Phase III studies contributed data to the Phase IIA outcomes. 
Together these studies provide data relating to 37,173 patients and 67 drug combinations.  
Figure 2 summarises numbers of studies and patients pertaining to each drug combination 
across all the outcomes of interest. Since only combinations including drugs of interest to the 
review are summarised, in some cases only data concerning the control arms of trials are 
presented. Additionally, studies with two or more trial arms were analysed separately. The 
composition of each drug combination refers only to the period preceding the endpoint of 
interest. Therefore, for the eight week culture outcome usually only drugs used in the initiation 
phase of treatment are reported without the associated continuation phase drugs. Where the 
initiation phase was less than two months, however, continuation drugs are also listed. The 
regimens for which most data were available were HRZE, SHRZ and HRZ combination 
therapy.  
Twenty-four studies reported Phase IIA outcomes. EBA0-2 was reported in all 24 studies (141 
trial arms, 35 drug combinations, 1424 patients). In some cases, studies considered the same 
drug combination but different treatment strategies and dosing intervals. Others considered 
single formulation treatments versus combined formulations, and some considered multiple 
dosages of a drug. EBA0-7 and EBA0-14 were reported in only six (23 trial arms, 14 drug 
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combinations, 296 patients) and eight studies (46 trial arms, 27 drug combinations, 449 
patients) respectively. 
The proportion of patients culture negative by eight weeks was reported in 104 studies 
considering Phase IIB outcomes. These studies investigated 45 different drug combinations in 
34,418 patients. One study reported both Phase IIA and Phase IIB outcomes [13]. 
Forest plots for each drug combination and outcome and associated numerical results are 
presented in the Appendix. Results shown in Figures 3 to 8 are graphical summaries based on 
standard doses recommended in treatment guidelines in the case of historic drugs, or doses 
going into Phase III trials in the case of novel drugs. 
Risk of Bias 
87 (65%) studies provided information on sequence generation. In most cases (94%) patients 
were "randomly allocated" so studies were classified as unclear risk of bias. Some publications 
mentioned stratifying by factors such as severity, or used permuted block designs, random 
tables, or similar and were classified as low risk of bias. Five studies referred to quasi-
randomisation and were therefore classified as high risk of bias. 
Only 30 (23%) studies mentioned allocation concealment. Of these, 28 (93%) studies used 
sealed envelopes and were classified as low risk. 97 (73%) studies either reported that the study 
was un-blinded, or did not specify blinding procedures and were classified as high risk of bias. 
15 included studies were of a double-blinded nature including the use of telephone 
randomisation, or prearranged lists, although one stated that it was double-blind during the 
maintenance phase of treatment only [14]. Most other blinded studies mentioned that 
radiographers or laboratory staff were blinded to treatment - these were considered as single-
blinded designs and classified as low risk of bias. 
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97 (73%) of studies were published pre-CONSORT when selective reporting had not been 
raised as a possible source of bias. In all studies published post-CONSORT, the risk of bias is 
unclear as there is insufficient information to determine whether the published reports include 
all expected outcomes, including those pre-specified. 85 (64%) studies reported reasons for 
exclusions, or numbers lost to follow-up. 
Due to the limited number of high quality studies, sensitivity analyses assessing the impact of 
risk of bias was not performed. 
Phase IIA Studies 
EBA0-2  
Pooled results for the EBA0-2 outcome can be seen in Figure 3. Of the 32 drugs and 
combinations, only five were studied in more than 30 patients. Hence the confidence intervals 
on pooled estimates of effect are wide and frequently overlap. Some drugs (Rb, Z, J and S) do 
not demonstrate any significant efficacy on this endpoint and can also clearly be distinguished 
from H, the most commonly studied and precisely estimated drug. However, even quite 
commonly studied combinations containing H such as HRZ, HRZE and SHRZ do not appear 
significantly different from H monotherapy using the EBA0-2 endpoint. Similarly, it does not 
appear possible to separate the effect of HRZE from any of its component drugs, with the 
exception of Z. 
EBA0-7 and EBA0-14  
Pooled results for the EBA0-7 and EBA0-14 outcomes can be seen in Figures 4 and 5 respectively. 
Although the number of studies reporting these endpoints was fewer, variability of these 
endpoints appeared lower than for EBA0-2. Even so, it did not appear possible to distinguish 
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statistically between the drugs and regimens studied, including combinations such as HRZE 
and drugs as diverse as H, Pa and J.  
Phase IIB Studies 
Figures 6 to 8 summarise the pooled estimates of the proportion of patients culture negative at 
eight weeks, grouped by culture method. The overall point estimates of culture conversion for 
the most effective rifampicin-containing regimens on this endpoint (HRZ, SHRZ and HRZE) 
exceeded 85% while for most non-rifampicin regimens this estimate was no better than 50%. 
Though relatively precise estimates were obtained for frequently studied modern short-course 
regimens such as HRZ, SHRZ and HRZE, the performance of these regimens was not 
statistically distinguishable from historical regimens comprising similar numbers of trials and 
patients such as HS, HPS or SHR. This appeared to reflect high inter-trial variability within 
regimens as measured by I2 and τ2 estimated using two approaches (see Appendix).  
Fewer data were available relating to culture conversion as measured by liquid culture. 
Although variability appeared lower than with solid culture, this could be due to the smaller 
number of studies included in this analysis. Variability increased when pooled results based on 
solid and liquid culture methods were reported and confidence intervals for all the regimens 
tested using liquid culture results overlapped. 
Meta-regression 
The results of meta-regression analyses can be seen in Table 1. For the selected drug 
combinations HRZE, HRZ and SHRZ neither year of publication nor geographical location 
were statistically significant. HIV co-infection could only be examined for the drug 
combination HRZE as there was insufficient data for HRZ and SHRZ. It was also not 
significantly associated with the proportion of patients who were culture negative at either 
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weeks. The inclusion of R and Z in a regimen independently explained significant 
heterogeneity among drug combinations (see Appendix). 
Ranking 
Since it was difficult to discriminate between regimens in terms of formal statistical inference, 
we evaluated whether the rank order of regimens was consistent between different endpoints. 
The ranking however was highly constrained by the limited number of drugs and regimens 
studied in both phases, principally because of the ethical unacceptability of prolonged 
monotherapy in two month studies and the lack of historical combination EBA studies.  
Nine distinct regimens (HRZE, H, J, JPa, JZ, Pa, PaMZ, PaZ, and R) were considered on at 
least two Phase IIA endpoints. All nine were considered when examining EBA0-2, and all except 
Pa were considered when examining EBA0-7. Seven were considered (H, HPa, HZ, Pa, PaMZ, 
and PaZ) when examining EBA0-14. Only three of these regimens (HRZE, H, and R) were 
considered for two month culture conversion on solid media.  
Using the relative order among the drugs in the common sets and basing results only on solid 
culture, the rankings are shown in Table 2. Though qualitative rankings for the available 
regimens were reasonably consistent the dataset was too small to be able to draw conclusions 
about their usefulness for decision making. 
 
Discussion 
This review is the first to systematically appraise the performance of single drugs and 
combination regimens across early clinical endpoints in trials of treatment of pulmonary 
tuberculosis. Though we focussed only on the set of drugs most relevant to historical and 
modern first-line therapy, we identified 133 trials reporting Phase IIA and IIB outcomes 
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comprising more than 37,000 patients and 67 drug combinations. However, the diversity of 
treatment regimens represented in 14 day Phase IIA studies was much lower, with only nine 
drug combinations assessed on more than one Phase IIA endpoint and only three of these 
combinations assessed in both Phase IIA and IIB trials. While these findings partly reflect the 
history, development and differing goals of such trials, the narrowness of this evidence base is 
concerning and suggests a potentially serious gap in rational translation between these two 
critical phases of development. While rankings of the efficacy of treatment appeared 
reasonably consistent on different Phase IIA endpoints, the existing dataset does not provide 
convincing support to current practices and inter-trial variability was high in many cases. 
We selected four outcome measures for our review based on those most commonly reported in 
the included studies [15]. However, there was large variation in reporting, particularly of EBA 
measures, with many unique to a single study. Overall the quality of reporting, particularly of 
Phase IIA studies made data extraction and synthesis challenging and imposes limitations in 
interpretation of the data. The striking feature of the available dataset is the variability of pooled 
estimates of effect for all the endpoints examined. For EBA0-2 and two month culture 
conversion, this variability was particularly marked, with overlapping confidence intervals for 
the majority of regimens. Though there were appreciable differences between the best-
performing regimens on these endpoints (H, HRZ, HRZE and SHRZ) and the worst (Z, S, SH 
and SHP), this suggests that such trials may lack the power to formally discriminate between 
regimens where differences in treatment effect are more modest but still clinically relevant. 
The reasons for this variability were difficult to explore using the data available, given the 
quality and consistency of reporting.  
We used the data as reported – some studies adopted an intention to treat approach to analysis 
and included patients with missing or contaminated culture results, while others used a per 
protocol approach and excluded these patients. Poor quality reporting meant it was mostly 
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impossible to distinguish these situations. This may account for some of the observed 
heterogeneity.  
The variance of the pooled estimates for EBA endpoints may be inflated by the regression 
coefficients being based on different numbers of observations. There were no such 
methodological problems for the two month culture-conversion results, suggesting that the 
observed heterogeneity is likely to be a real clinical effect. Among the most likely sources of 
this within-regimen heterogeneity are pharmacological (ethnic differences in absorption, 
elimination and clearance), bacteriological (differences in initial bacterial burden, and 
virulence) and patient factors (disease stage such as presence of cavities, co-morbidities such 
as malnutrition, diabetes, and HIV).Our meta-regression analysis was able to explore a very 
limited subset of such variables for a few of the most common regimens on a single endpoint.  
Since the review incorporated all reported trials over the last sixty years, evolution in the 
efficiency and standardisation even of solid culture methods may have contributed to variation 
in two month culture results, with older studies tending to produce numerically higher rates 
(not statistically significant) of culture conversion due to lower assay sensitivity compared to 
more modern methods. We tested this via meta-regression for drug combinations HRZE, HRZ 
and SHRZ and in all three cases year of publication was not significant. Isoniazid resistance, 
whether known or undetected, may have tended to increase heterogeneity in outcomes, but this 
is difficult to assess due to small numbers of patients. While it is known that at least for modern 
regimens such as HRZE the risk of poor outcome for patients with H-resistant organisms is 
only modestly increased [16, 17] this could be more important for older regimens although 
there was insufficient data to test this in a meta-regression. Finally, patient factors particularly 
chronicity of disease, geographical location and HIV co-infection could also have increased 
inter-trial variability within regimens although there was insufficient data to test this for 
chronicity of disease. It has been observed that culture conversion at two months may vary 
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widely even between study sites in individual trials [18] and may be influenced by the lower 
sputum bacillary load observed in HIV+ patients. 
We propose three approaches which could help to overcome some of the limitations this review 
identifies in the existing evidence base for Phase II trials in TB. Firstly, assembly of a database 
of individual patient data relating to the trials identified would facilitate re-analysis of the trials 
and also enable computation of endpoints not reported in the original study publication, which 
may help to address the lack of diversity of regimens on each endpoint. Such an effort is 
currently in progress by the PreDiCT-TB consortium and we anticipate an update of this review 
based on individual patient data when that process has been completed.  
Second, development of a core outcome set for tuberculosis trials which could be applied to 
new studies in the field would likely assist both investigators and systematic reviewers in 
choosing and reporting endpoints in such a way that the contribution of each trial to the overall 
evidence base is maximised [19]. This would provide a minimum but not exhaustive set of 
clearly defined outcomes to be reported in each study. 
Finally, we also suggest wider use of novel, more efficient, adaptive screening trial designs 
which would enable a broader range of regimens to be studied in Phase II than was previously 
possible. However, such trials may also impact any meta-analysis to which they contribute in 
terms of the endpoints that they prioritise and any bias they might introduce due to early 
termination. 
Our review shows that the existing evidence base supporting Phase II methodology in 
tuberculosis is highly incomplete. To truly understand and improve drug development in 
tuberculosis, it is desirable that a broader range of drugs and combinations be more consistently 
studied across a greater range of Phase II endpoints than is currently available and that these 
regimens be rigorously compared in a cumulative meta-analytic framework. Though this 
13 
 
review forms an initial contribution, achieving this goal will require a coordinated and 
multidisciplinary effort by the TB trials community. 
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Tables 
Table 1: Meta-regression results for the impact of selected variables on the proportion of 
patients who were culture negative at eight weeks – beta coefficients describe how the 
outcome variable changes with a unit increase in the explanatory variable 
 Covariate – beta regression coefficient (p-values) 
Drugs Year of Publication 
Proportion of patients 
with HIV co-infection 
Geographical location 
(Africa or not) 
HRZE -0·00 (0·27) 0·00 (0·79) 0·01 (0·87) 
HRZ 0·01 (0·24) Insufficient data* -0·12 (0·45) 
SHRZ 0·00 (0·57) Insufficient data** -0·08 (0·17) 
* Only one study presented proportion of patients with HIV co-infection 
**No studies presented proportion of patients with HIV co-infection 
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Table 2: Ranking of Drugs Across Outcomes based on a subset of regimens for which at least 
two of the EBA results were available. 
Drug(s) EBA0-2: Ranking 
Patients (Regimens) 
EBA0-7: Ranking  
Patients (Regimens) 
EBA0-14: Ranking  
Patients (Regimens) 
2 month: Ranking  
Patients (Regimens) 
H 1 
149 (16) 
1 
36 (4) 
- 3 
533 (6) 
HRZE 2 
51 (6) 
4 
21 (2) 
2 
50 (6) 
1 
1618 (8) 
PaMZ 3 
15 (1) 
3 
12 (1) 
1 
13 (1) 
- 
R 4 
28 (3) 
2 
13 (1) 
- 2 
77 (2) 
PaZ 5 
15 (1) 
5 
14 (1) 
3 
14 (1) 
- 
Pa 6 
29 (2) 
- 6 
26 (2) 
- 
JPa 7 
14 (1) 
6 
14 (1) 
5 
14 (1) 
- 
JZ 8 
15 (1) 
7 
15 (1) 
4 
15 (1) 
- 
J 9 
41 (3) 
8 
26 (2) 
7 
28 (2) 
- 
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Figure Legends 
Figure 1: Literature Review process 
Figure 2: Drug Combinations of Included Studies 
Figure 3: EBA0-2 Day Results (fixed effects – Generalised Inverse Variance Method) 
Figure 4: EBA0-7 Days (fixed effects – Generalised Inverse Variance Method) 
Figure 5: EBA0-14 Days (fixed effects – Generalised Inverse Variance Method) 
Figure 6: Culture Negativity at eight weeks - Solid Culture (random effects – DerSimonian and Laird 
Method) 
Figure 7: Culture Negativity at eight weeks - Liquid Culture (random effects – DerSimonian and 
Laird Method) 
Figure 8: Culture Negativity at eight weeks – Solid & Liquid Culture (random effects – DerSimonian 
and Laird Method) 
 
